サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1579661

静脈ステントの世界市場

Venous Stents

出版日
ページ情報
英文 193 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.96円
静脈ステントの世界市場
出版日: 2024年10月30日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 193 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

静脈ステントの世界市場は2030年までに21億米ドルに達する見込み

2023年に12億米ドルと推定される静脈ステントの世界市場は、2030年には21億米ドルに達し、分析期間2023-2030年のCAGRは8.4%で成長すると予測されます。本レポートで分析したセグメントの1つである腸骨静脈ステント技術は、CAGR 8.3%を記録し、分析期間終了時には14億米ドルに達すると予測されます。壁ステント技術セグメントの成長率は、分析期間でCAGR 8.5%と推定されます。

米国市場は3億1,900万米ドルと推定、中国はCAGR11.2％で成長予測

米国の静脈ステント市場は、2023年に3億1,900万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2023-2030年のCAGR11.2％を追いかけ、2030年までに4億7,450万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ5.5%と6.7%と予測されています。欧州では、ドイツがCAGR約6.5%で成長すると予測されています。

世界の静脈ステント市場- 主要動向と市場促進要因を探る

なぜ静脈ステントは血管疾患管理で重要性を増しているのか？

静脈ステントは、静脈閉塞、深部静脈血栓症（DVT）、その他の血管疾患を患う患者に低侵襲のソリューションを提供し、慢性静脈疾患の管理における重要なツールとして登場しました。しかし、これらの器具が現代の血管治療に不可欠なのはなぜなのだろうか？静脈ステントは、適切な血流を回復し、静脈の虚脱や閉塞を防ぐために静脈に挿入されるメッシュ状の小さな金属管です。このステントは、静脈不全（静脈が下肢から心臓に血液を効果的に戻すことができず、痛みや腫れ、静脈瘤などの症状を引き起こす状態）に対処するために特別に設計されています。高圧の血流を扱う動脈に使用される動脈ステントとは異なり、静脈ステントは血圧が低く、異なる構造特性を持つ静脈に最適化されています。そのデザインは、柔軟性と血管壁への適合性を確保するため、静脈の開存性を維持し、静脈閉塞に伴う症状を緩和するのに非常に効果的です。

静脈ステントの需要を牽引しているのは、世界中で数百万人が罹患し、放置すると深刻な合併症を引き起こす可能性のある慢性静脈障害の有病率の増加です。圧迫療法や抗凝固薬などの従来の治療法では、進行した静脈閉塞の管理には不十分な場合が多く、ステント留置術が好ましい治療法となっています。静脈ステントは、狭窄または閉塞した静脈を物理的に開通させることで、血流を改善し、下腿潰瘍や血栓症の再発といった合併症のリスクを低減し、長期的な解決策を提供します。静脈ステントの採用は、血栓後症候群（PTS）や腸骨静脈圧迫症候群（May-Thurner症候群）などの治療において特に多く、ステント留置術は患者の転帰とQOLを著しく改善することが示されています。静脈疾患とステント留置の利点に対する認識が高まるにつれ、ヘルスケアプロバイダーは複雑な静脈病変に対する第一選択として静脈ステントを選択するようになってきています。

技術革新は静脈ステントの有効性をどのように高めていますか？

静脈ステント市場は、これらのデバイスの安全性、有効性、耐久性を向上させる重要な技術的進歩を目の当たりにしてきました。しかし、これらの発展の原動力となっている主な技術革新とは何でしょうか？最も注目すべき進歩のひとつは、静脈特有の解剖学的・生理学的課題に対応する静脈専用ステントの開発です。当初は動脈用に設計された従来のステントは、静脈の生体力学的特性が異なるため、静脈の環境で使用すると最適な結果が得られないことが多かった。これに対し、各メーカーは、柔軟性、径方向への力、キンクや圧迫に対する耐性などの特徴を備えた静脈専用のステントを発売しています。これらのステントは、曲がりくねった血管や高度に湾曲した血管であっても、静脈の解剖学的構造に適合するように設計されており、長期的な開存性を確保し、移動や破折のリスクを最小限に抑えています。さらに、ステントの構造にニチノールやコバルトクロム合金を使用することで、強度と弾力性が向上し、大口径の静脈や高圧縮部位に適しています。

もう一つの重要な技術革新は、薬物溶出性ステントのイントロダクションです。このステントは、組織の過剰な増殖を防ぎ、ステント内再狭窄のリスクを低減する薬理学的薬剤でコーティングされています。動脈ステントですでに成功を収めているこの技術は、再狭窄のリスクが重要な懸念事項である静脈ステントでも有望視されています。薬剤溶出ステントは、時間の経過とともに抗増殖薬を放出し、ステント内の瘢痕組織の増殖を抑制して内腔の開存性を維持します。さらに、血管内超音波（IVUS）やデジタルサブトラクション血管造影（DSA）などの画像技術の進歩により、ステント留置の精度が向上し、静脈の形態をより正確に評価できるようになり、ステントが最適な位置に留置されるようになった。これらの技術の統合は、静脈ステントの安全性と有効性を向上させただけでなく、多段階の静脈閉塞や再発性DVTなど、より複雑な症例への使用も拡大しました。その結果、静脈ステントの幅広い静脈疾患に対する有効性が著しく向上し、臨床現場での採用が進んでいます。

どのような市場動向が血管治療における静脈ステントの採用を促進していますか？

血管治療における静脈ステントの採用には、患者とヘルスケアプロバイダー双方のニーズの進化を反映した、いくつかの新たな市場動向があります。最も顕著な動向の一つは、低侵襲手技への注目の高まりです。患者や臨床医が、回復時間の短縮、合併症発生率の低下、入院期間の短縮を優先するにつれ、静脈疾患に対する血管内治療への強いシフトが見られます。低侵襲な選択肢である静脈ステント留置術は、従来の開腹手術に比べて外傷が少なく、慢性静脈不全や静脈閉塞の管理に好ましい選択肢となっています。この動向は特に先進地域で顕著であり、高度なヘルスケア・インフラと患者の高い意識レベルが、低侵襲手技の広範な採用を支えています。また、外来処置へのシフトも静脈ステントの需要を後押ししています。これらのデバイスは多くの場合、その日のうちに移植できるため、患者の日常生活への支障を最小限に抑えることができるからです。

静脈ステントの採用を促進するもう一つの重要な動向は、慢性静脈障害が公衆衛生上の大きな問題であるとの認識が高まっていることです。世界人口の高齢化、肥満、座りがちなライフスタイル、長時間の不動などの危険因子の増加により、静脈疾患の有病率は上昇傾向にあります。このため、早期診断と早期介入の重要性に対するヘルスケアプロバイダーや患者の意識が高まっています。その結果、静脈閉塞が静脈潰瘍や肺塞栓症などの重篤な合併症に至る前に、スクリーニングと治療を行うことが重視されるようになってきています。静脈ステントの採用は、静脈疾患の管理におけるステント留置術の役割を強調する臨床ガイドラインやコンセンサスステートメントの発表によってさらに後押しされています。これらのガイドラインは、主要な血管学会によって発行され、患者選択、手技、手技後の管理について明確化され、臨床の場での静脈ステントの普及と標準化を促進しています。これらの動向は、静脈疾患のより積極的で効果的な管理への幅広いシフトを反映しており、静脈ステントを現代の血管治療戦略の要として位置づけています。

静脈ステント世界市場の成長を促進する要因は？

静脈ステントの世界市場の成長は、ステント技術の進歩、静脈疾患の有病率の増加、低侵襲手術に対する需要の高まりなど、いくつかの要因によって牽引されています。主な成長要因の一つは、PTSや腸骨静脈圧迫などの複雑な静脈病変の治療における静脈ステントの使用拡大です。これらの疾患に対する認識が高まり、診断能力が向上するにつれて、ステント留置術の適応とされる患者が増え、静脈ステントの需要増につながっています。静脈の解剖学的課題に対処するために特別に設計された静脈ステント専用器具が利用できるようになったことも、従来のステントと比較して優れた臨床結果をもたらすことから、市場の成長に寄与しています。柔軟性、半径方向の強度、圧迫に対する抵抗力が強化された次世代ステントの開発により、静脈ステント留置術の恩恵を受けられる患者の範囲がさらに拡大し、静脈閉塞の一次および再発の両方の症例で採用が進んでいます。

もうひとつの主な成長要因は、医療機器メーカーによる研究開発への投資の増加です。競争が激化する中、メーカー各社は患者や臨床医のアンメットニーズに対応するため、改良されたデザインと高度なコーティングを備えた革新的な静脈ステントの開発に注力しています。これらの新しいステントの長期的な安全性と有効性を実証する臨床試験や研究は、医療従事者の信頼構築に役立っており、臨床現場におけるこれらの機器の普及を後押ししています。さらに、特に高齢者層における慢性静脈疾患の負担の増加により、より効果的な治療オプションに対するニーズが高まっています。世界人口の高齢化に伴い静脈疾患の有病率は増加すると予想され、静脈ステントの需要はさらに高まっています。保険償還政策が支持され、ステント留置術の臨床的利点が認識されつつあることから、静脈ステントの世界市場は、技術革新、臨床採用、人口動向のダイナミックな相互作用によって、持続的な成長が見込まれています。

調査対象企業の例（注目の43社）

  • BARD, A Becton, Dickinson Company
  • Boston Scientific Corporation
  • Cook Medical LLC
  • Gore Medical
  • Jotec GmbH
  • OptiMed Medizinische Instrumente GmbH

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP16887

Global Venous Stents Market to Reach US$2.1 Billion by 2030

The global market for Venous Stents estimated at US$1.2 Billion in the year 2023, is expected to reach US$2.1 Billion by 2030, growing at a CAGR of 8.4% over the analysis period 2023-2030. Iliac Vein Stent Technology, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Wallstent Technology segment is estimated at 8.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$319.0 Million While China is Forecast to Grow at 11.2% CAGR

The Venous Stents market in the U.S. is estimated at US$319.0 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$474.5 Million by the year 2030 trailing a CAGR of 11.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.5% and 6.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR.

Global Venous Stents Market - Key Trends & Growth Drivers Explored

Why Are Venous Stents Gaining Importance in Vascular Disease Management?

Venous stents have emerged as a crucial tool in the management of chronic venous diseases, offering a minimally invasive solution for patients suffering from venous obstructions, deep vein thrombosis (DVT), and other vascular conditions. But what makes these devices so essential in modern vascular care? Venous stents are small, mesh-like metal tubes inserted into veins to restore proper blood flow and prevent vein collapse or blockage. They are specifically designed to address venous insufficiencies, a condition where veins are unable to effectively return blood from the lower extremities back to the heart, causing symptoms like pain, swelling, and varicose veins. Unlike arterial stents, which are used in arteries that handle high-pressure blood flow, venous stents are optimized for veins with lower blood pressure and different structural characteristics. Their design ensures flexibility and conformity to the vessel wall, making them highly effective for maintaining vein patency and alleviating symptoms associated with venous obstruction.

The demand for venous stents is driven by the increasing prevalence of chronic venous disorders, which affect millions of people worldwide and can lead to severe complications if left untreated. Traditional treatment options, such as compression therapy and anticoagulant medication, often fall short in managing advanced cases of venous obstruction, making stenting a preferred therapeutic option. Venous stents offer a long-lasting solution by physically opening narrowed or blocked veins, thereby improving blood flow and reducing the risk of complications like leg ulcers and recurrent thrombosis. The adoption of venous stents is particularly prevalent in the treatment of conditions such as post-thrombotic syndrome (PTS) and iliac vein compression syndrome (May-Thurner syndrome), where stenting has been shown to significantly improve patient outcomes and quality of life. As awareness of venous diseases and the benefits of stenting continues to grow, healthcare providers are increasingly opting for venous stents as a first-line intervention for complex venous pathologies.

How Are Technological Innovations Enhancing the Effectiveness of Venous Stents?

The venous stents market has witnessed significant technological advancements that have improved the safety, efficacy, and durability of these devices. But what are the key innovations driving these developments? One of the most notable advancements is the development of dedicated venous stent designs that address the unique anatomical and physiological challenges of veins. Traditional stents, initially designed for arterial applications, often struggled to provide optimal outcomes when used in venous settings due to the different biomechanical properties of veins. In response, manufacturers have introduced venous-specific stents with features such as greater flexibility, radial force, and resistance to kinking and compression. These stents are engineered to conform to the venous anatomy, even in tortuous or highly curved vessels, ensuring long-term patency and minimizing the risk of migration or fracture. Additionally, the use of nitinol and cobalt-chromium alloys in stent construction has enhanced their strength and elasticity, making them better suited for large-diameter veins and high-compression areas.

Another critical innovation is the introduction of drug-eluting venous stents, which are coated with pharmacological agents that prevent excessive tissue growth and reduce the risk of in-stent restenosis. This technology, already successful in arterial stents, has shown promise in venous applications, where the risk of restenosis is a significant concern. Drug-eluting stents release anti-proliferative drugs over time, inhibiting the growth of scar tissue within the stent and maintaining lumen patency. Moreover, advancements in imaging technologies, such as intravascular ultrasound (IVUS) and digital subtraction angiography (DSA), have enhanced the precision of stent placement, allowing for more accurate assessment of vein morphology and ensuring that the stent is optimally positioned. The integration of these technologies has not only improved the safety and efficacy of venous stents but has also expanded their use in more complex cases, such as multi-level venous obstructions and recurrent DVT. As a result, the effectiveness of venous stents in treating a broader range of venous diseases has been significantly enhanced, driving their adoption in clinical practice.

What Market Trends Are Driving the Adoption of Venous Stents in Vascular Treatment?

Several emerging market trends are shaping the adoption of venous stents in vascular treatment, reflecting the evolving needs of both patients and healthcare providers. One of the most prominent trends is the increasing focus on minimally invasive procedures. As patients and clinicians prioritize faster recovery times, lower complication rates, and reduced hospital stays, there has been a strong shift towards endovascular treatments for venous diseases. Venous stenting, as a minimally invasive option, offers a less traumatic alternative to traditional open surgery, making it a preferred choice for managing chronic venous insufficiency and venous obstructions. This trend is particularly evident in developed regions, where advanced healthcare infrastructure and high patient awareness levels support the widespread adoption of minimally invasive techniques. The shift towards outpatient procedures has also driven the demand for venous stents, as these devices can often be implanted in a same-day setting, minimizing disruption to patients’ daily lives.

Another significant trend driving the adoption of venous stents is the growing recognition of chronic venous disorders as a major public health issue. With an aging global population and rising incidence of risk factors such as obesity, sedentary lifestyles, and prolonged immobility, the prevalence of venous diseases is on the rise. This has led to increased awareness among healthcare providers and patients about the importance of early diagnosis and intervention. As a result, there is a growing emphasis on screening and treating venous obstructions before they lead to more severe complications, such as venous ulcers or pulmonary embolism. The adoption of venous stents has been further supported by the publication of clinical guidelines and consensus statements that highlight the role of stenting in managing venous diseases. These guidelines, issued by leading vascular societies, have provided clarity on patient selection, procedural techniques, and post-procedure management, facilitating more widespread and standardized use of venous stents across clinical settings. These trends reflect a broader shift towards more proactive and effective management of venous diseases, positioning venous stents as a cornerstone of modern vascular treatment strategies.

What Factors Are Driving the Growth of the Global Venous Stents Market?

The growth in the global venous stents market is driven by several factors, including advancements in stent technology, increasing prevalence of venous disorders, and the rising demand for minimally invasive procedures. One of the primary growth drivers is the expanding use of venous stents in the treatment of complex venous pathologies, such as PTS and iliac vein compression. As awareness of these conditions grows and diagnostic capabilities improve, more patients are being identified as candidates for stenting, leading to increased demand for venous stents. The availability of dedicated venous stents that are specifically designed to address the challenges of venous anatomy has also contributed to market growth, as these devices offer better clinical outcomes compared to traditional stents. The development of next-generation stents with enhanced flexibility, radial strength, and resistance to compression has further expanded the range of patients who can benefit from venous stenting, driving adoption in both primary and recurrent cases of venous obstruction.

Another key growth driver is the increasing investment in research and development by medical device companies. As competition intensifies, manufacturers are focusing on developing innovative venous stents with improved designs and advanced coatings to address the unmet needs of patients and clinicians. Clinical trials and studies demonstrating the long-term safety and efficacy of these new stents are helping to build confidence among healthcare providers, encouraging more widespread use of these devices in clinical practice. Additionally, the rising burden of chronic venous diseases, particularly in aging populations, is creating a need for more effective treatment options. The prevalence of venous disorders is expected to increase as the global population ages, further fueling demand for venous stents. With supportive reimbursement policies and the growing recognition of the clinical benefits of stenting, the global venous stents market is poised for sustained growth, driven by a dynamic interplay of technological innovation, clinical adoption, and demographic trends.

Select Competitors (Total 43 Featured) -

  • BARD, A Becton, Dickinson Company
  • Boston Scientific Corporation
  • Cook Medical LLC
  • Gore Medical
  • Jotec GmbH
  • OptiMed Medizinische Instrumente GmbH

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Venous Stents - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Chronic Venous Insufficiency and Deep Vein Thrombosis Drives Demand for Venous Stents
    • Increased Adoption of Minimally Invasive Vascular Procedures Expands Addressable Market for Venous Stents
    • Surge in Demand for Venous Stents in Post-Thrombotic Syndrome Treatment Fuels Market Growth
    • Rising Adoption of Venous Stents in Outpatient and Ambulatory Surgical Centers Sets the Stage for Market Growth
    • Surge in Use of Venous Stents for Treating Pelvic and Iliac Vein Compression Expands Market Opportunities
    • Technological Innovations in Drug-Eluting and Bioabsorbable Venous Stents Propel Market Growth
    • Rising Utilization of Venous Stents in Cancer and Post-Surgical Complications Fuels Market Demand
    • Surge in Adoption of Venous Stents in Pediatric and Geriatric Venous Disorders Expands Market Opportunities
    • Technological Advancements in Imaging and Navigation Systems for Venous Stenting Propel Market Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Venous Stents Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Venous Stents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Venous Stents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Venous Stents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Iliac Vein Stent Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Iliac Vein Stent Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Iliac Vein Stent Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Wallstent Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Wallstent Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Wallstent Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Leg by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Leg by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Leg by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Chest by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Chest by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Chest by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Abdomen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Abdomen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Abdomen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Arm by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Arm by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Arm by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Chronic Deep Vein Thrombosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Chronic Deep Vein Thrombosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Chronic Deep Vein Thrombosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Post Thrombotic Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Post Thrombotic Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Post Thrombotic Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for May-Thurner Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for May-Thurner Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for May-Thurner Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Hemodialysis/Arteriovenous Fistulae by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Hemodialysis/Arteriovenous Fistulae by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Hemodialysis/Arteriovenous Fistulae by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Other Disease Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Venous Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Venous Stents by Technology - Percentage Breakdown of Value Sales for Iliac Vein Stent Technology and Wallstent Technology for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Venous Stents by Application - Leg, Chest, Abdomen and Arm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Venous Stents by Application - Leg, Chest, Abdomen and Arm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Venous Stents by Application - Percentage Breakdown of Value Sales for Leg, Chest, Abdomen and Arm for the Years 2014, 2024 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Venous Stents by Disease Indication - Percentage Breakdown of Value Sales for Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Venous Stents by Technology - Percentage Breakdown of Value Sales for Iliac Vein Stent Technology and Wallstent Technology for the Years 2014, 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Venous Stents by Application - Leg, Chest, Abdomen and Arm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Venous Stents by Application - Leg, Chest, Abdomen and Arm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Venous Stents by Application - Percentage Breakdown of Value Sales for Leg, Chest, Abdomen and Arm for the Years 2014, 2024 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Venous Stents by Disease Indication - Percentage Breakdown of Value Sales for Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications for the Years 2014, 2024 & 2030
  • JAPAN
    • Venous Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Venous Stents by Technology - Percentage Breakdown of Value Sales for Iliac Vein Stent Technology and Wallstent Technology for the Years 2014, 2024 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Venous Stents by Application - Leg, Chest, Abdomen and Arm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Venous Stents by Application - Leg, Chest, Abdomen and Arm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Venous Stents by Application - Percentage Breakdown of Value Sales for Leg, Chest, Abdomen and Arm for the Years 2014, 2024 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Venous Stents by Disease Indication - Percentage Breakdown of Value Sales for Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications for the Years 2014, 2024 & 2030
  • CHINA
    • Venous Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Venous Stents by Technology - Percentage Breakdown of Value Sales for Iliac Vein Stent Technology and Wallstent Technology for the Years 2014, 2024 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Venous Stents by Application - Leg, Chest, Abdomen and Arm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Venous Stents by Application - Leg, Chest, Abdomen and Arm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Venous Stents by Application - Percentage Breakdown of Value Sales for Leg, Chest, Abdomen and Arm for the Years 2014, 2024 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: China 16-Year Perspective for Venous Stents by Disease Indication - Percentage Breakdown of Value Sales for Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications for the Years 2014, 2024 & 2030
  • EUROPE
    • Venous Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Venous Stents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Venous Stents by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Venous Stents by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Venous Stents by Technology - Percentage Breakdown of Value Sales for Iliac Vein Stent Technology and Wallstent Technology for the Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Venous Stents by Application - Leg, Chest, Abdomen and Arm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Venous Stents by Application - Leg, Chest, Abdomen and Arm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Venous Stents by Application - Percentage Breakdown of Value Sales for Leg, Chest, Abdomen and Arm for the Years 2014, 2024 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Venous Stents by Disease Indication - Percentage Breakdown of Value Sales for Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications for the Years 2014, 2024 & 2030
  • FRANCE
    • Venous Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Venous Stents by Technology - Percentage Breakdown of Value Sales for Iliac Vein Stent Technology and Wallstent Technology for the Years 2014, 2024 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Venous Stents by Application - Leg, Chest, Abdomen and Arm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Venous Stents by Application - Leg, Chest, Abdomen and Arm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Venous Stents by Application - Percentage Breakdown of Value Sales for Leg, Chest, Abdomen and Arm for the Years 2014, 2024 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: France 16-Year Perspective for Venous Stents by Disease Indication - Percentage Breakdown of Value Sales for Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications for the Years 2014, 2024 & 2030
  • GERMANY
    • Venous Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Venous Stents by Technology - Percentage Breakdown of Value Sales for Iliac Vein Stent Technology and Wallstent Technology for the Years 2014, 2024 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Venous Stents by Application - Leg, Chest, Abdomen and Arm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Venous Stents by Application - Leg, Chest, Abdomen and Arm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Venous Stents by Application - Percentage Breakdown of Value Sales for Leg, Chest, Abdomen and Arm for the Years 2014, 2024 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Venous Stents by Disease Indication - Percentage Breakdown of Value Sales for Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Venous Stents by Technology - Percentage Breakdown of Value Sales for Iliac Vein Stent Technology and Wallstent Technology for the Years 2014, 2024 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Venous Stents by Application - Leg, Chest, Abdomen and Arm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Venous Stents by Application - Leg, Chest, Abdomen and Arm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Venous Stents by Application - Percentage Breakdown of Value Sales for Leg, Chest, Abdomen and Arm for the Years 2014, 2024 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Venous Stents by Disease Indication - Percentage Breakdown of Value Sales for Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Venous Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Venous Stents by Technology - Percentage Breakdown of Value Sales for Iliac Vein Stent Technology and Wallstent Technology for the Years 2014, 2024 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Venous Stents by Application - Leg, Chest, Abdomen and Arm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Venous Stents by Application - Leg, Chest, Abdomen and Arm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Venous Stents by Application - Percentage Breakdown of Value Sales for Leg, Chest, Abdomen and Arm for the Years 2014, 2024 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Venous Stents by Disease Indication - Percentage Breakdown of Value Sales for Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Venous Stents by Technology - Percentage Breakdown of Value Sales for Iliac Vein Stent Technology and Wallstent Technology for the Years 2014, 2024 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Venous Stents by Application - Leg, Chest, Abdomen and Arm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Venous Stents by Application - Leg, Chest, Abdomen and Arm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Venous Stents by Application - Percentage Breakdown of Value Sales for Leg, Chest, Abdomen and Arm for the Years 2014, 2024 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Venous Stents by Disease Indication - Percentage Breakdown of Value Sales for Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Venous Stents by Technology - Percentage Breakdown of Value Sales for Iliac Vein Stent Technology and Wallstent Technology for the Years 2014, 2024 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Venous Stents by Application - Leg, Chest, Abdomen and Arm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Venous Stents by Application - Leg, Chest, Abdomen and Arm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Venous Stents by Application - Percentage Breakdown of Value Sales for Leg, Chest, Abdomen and Arm for the Years 2014, 2024 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Venous Stents by Disease Indication - Percentage Breakdown of Value Sales for Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Venous Stents by Technology - Percentage Breakdown of Value Sales for Iliac Vein Stent Technology and Wallstent Technology for the Years 2014, 2024 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Venous Stents by Application - Leg, Chest, Abdomen and Arm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Venous Stents by Application - Leg, Chest, Abdomen and Arm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Venous Stents by Application - Percentage Breakdown of Value Sales for Leg, Chest, Abdomen and Arm for the Years 2014, 2024 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Venous Stents by Disease Indication - Percentage Breakdown of Value Sales for Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Venous Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Venous Stents by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Venous Stents by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Venous Stents by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Venous Stents by Technology - Percentage Breakdown of Value Sales for Iliac Vein Stent Technology and Wallstent Technology for the Years 2014, 2024 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Venous Stents by Application - Leg, Chest, Abdomen and Arm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Venous Stents by Application - Leg, Chest, Abdomen and Arm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Venous Stents by Application - Percentage Breakdown of Value Sales for Leg, Chest, Abdomen and Arm for the Years 2014, 2024 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Venous Stents by Disease Indication - Percentage Breakdown of Value Sales for Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Venous Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Venous Stents by Technology - Percentage Breakdown of Value Sales for Iliac Vein Stent Technology and Wallstent Technology for the Years 2014, 2024 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Venous Stents by Application - Leg, Chest, Abdomen and Arm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Venous Stents by Application - Leg, Chest, Abdomen and Arm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Venous Stents by Application - Percentage Breakdown of Value Sales for Leg, Chest, Abdomen and Arm for the Years 2014, 2024 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Venous Stents by Disease Indication - Percentage Breakdown of Value Sales for Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications for the Years 2014, 2024 & 2030
  • INDIA
    • Venous Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: India 16-Year Perspective for Venous Stents by Technology - Percentage Breakdown of Value Sales for Iliac Vein Stent Technology and Wallstent Technology for the Years 2014, 2024 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Venous Stents by Application - Leg, Chest, Abdomen and Arm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Venous Stents by Application - Leg, Chest, Abdomen and Arm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: India 16-Year Perspective for Venous Stents by Application - Percentage Breakdown of Value Sales for Leg, Chest, Abdomen and Arm for the Years 2014, 2024 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: India 16-Year Perspective for Venous Stents by Disease Indication - Percentage Breakdown of Value Sales for Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Venous Stents by Technology - Percentage Breakdown of Value Sales for Iliac Vein Stent Technology and Wallstent Technology for the Years 2014, 2024 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Venous Stents by Application - Leg, Chest, Abdomen and Arm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Venous Stents by Application - Leg, Chest, Abdomen and Arm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Venous Stents by Application - Percentage Breakdown of Value Sales for Leg, Chest, Abdomen and Arm for the Years 2014, 2024 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Venous Stents by Disease Indication - Percentage Breakdown of Value Sales for Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Venous Stents by Technology - Percentage Breakdown of Value Sales for Iliac Vein Stent Technology and Wallstent Technology for the Years 2014, 2024 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Venous Stents by Application - Leg, Chest, Abdomen and Arm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Venous Stents by Application - Leg, Chest, Abdomen and Arm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Venous Stents by Application - Percentage Breakdown of Value Sales for Leg, Chest, Abdomen and Arm for the Years 2014, 2024 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Venous Stents by Disease Indication - Percentage Breakdown of Value Sales for Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Venous Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Venous Stents by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Venous Stents by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Venous Stents by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Venous Stents by Technology - Percentage Breakdown of Value Sales for Iliac Vein Stent Technology and Wallstent Technology for the Years 2014, 2024 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Venous Stents by Application - Leg, Chest, Abdomen and Arm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Venous Stents by Application - Leg, Chest, Abdomen and Arm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Venous Stents by Application - Percentage Breakdown of Value Sales for Leg, Chest, Abdomen and Arm for the Years 2014, 2024 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Venous Stents by Disease Indication - Percentage Breakdown of Value Sales for Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Venous Stents by Technology - Percentage Breakdown of Value Sales for Iliac Vein Stent Technology and Wallstent Technology for the Years 2014, 2024 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Venous Stents by Application - Leg, Chest, Abdomen and Arm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Venous Stents by Application - Leg, Chest, Abdomen and Arm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Venous Stents by Application - Percentage Breakdown of Value Sales for Leg, Chest, Abdomen and Arm for the Years 2014, 2024 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Venous Stents by Disease Indication - Percentage Breakdown of Value Sales for Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Venous Stents by Technology - Percentage Breakdown of Value Sales for Iliac Vein Stent Technology and Wallstent Technology for the Years 2014, 2024 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Venous Stents by Application - Leg, Chest, Abdomen and Arm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Venous Stents by Application - Leg, Chest, Abdomen and Arm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Venous Stents by Application - Percentage Breakdown of Value Sales for Leg, Chest, Abdomen and Arm for the Years 2014, 2024 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Venous Stents by Disease Indication - Percentage Breakdown of Value Sales for Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Venous Stents by Technology - Percentage Breakdown of Value Sales for Iliac Vein Stent Technology and Wallstent Technology for the Years 2014, 2024 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Venous Stents by Application - Leg, Chest, Abdomen and Arm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Venous Stents by Application - Leg, Chest, Abdomen and Arm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Venous Stents by Application - Percentage Breakdown of Value Sales for Leg, Chest, Abdomen and Arm for the Years 2014, 2024 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Venous Stents by Disease Indication - Percentage Breakdown of Value Sales for Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Venous Stents by Technology - Percentage Breakdown of Value Sales for Iliac Vein Stent Technology and Wallstent Technology for the Years 2014, 2024 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Venous Stents by Application - Leg, Chest, Abdomen and Arm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Venous Stents by Application - Leg, Chest, Abdomen and Arm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Venous Stents by Application - Percentage Breakdown of Value Sales for Leg, Chest, Abdomen and Arm for the Years 2014, 2024 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Venous Stents by Disease Indication - Percentage Breakdown of Value Sales for Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Venous Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Venous Stents by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Venous Stents by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Venous Stents by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Venous Stents by Technology - Percentage Breakdown of Value Sales for Iliac Vein Stent Technology and Wallstent Technology for the Years 2014, 2024 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Venous Stents by Application - Leg, Chest, Abdomen and Arm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Venous Stents by Application - Leg, Chest, Abdomen and Arm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Venous Stents by Application - Percentage Breakdown of Value Sales for Leg, Chest, Abdomen and Arm for the Years 2014, 2024 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Venous Stents by Disease Indication - Percentage Breakdown of Value Sales for Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Venous Stents by Technology - Percentage Breakdown of Value Sales for Iliac Vein Stent Technology and Wallstent Technology for the Years 2014, 2024 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Venous Stents by Application - Leg, Chest, Abdomen and Arm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Venous Stents by Application - Leg, Chest, Abdomen and Arm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Venous Stents by Application - Percentage Breakdown of Value Sales for Leg, Chest, Abdomen and Arm for the Years 2014, 2024 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Venous Stents by Disease Indication - Percentage Breakdown of Value Sales for Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Venous Stents by Technology - Percentage Breakdown of Value Sales for Iliac Vein Stent Technology and Wallstent Technology for the Years 2014, 2024 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Venous Stents by Application - Leg, Chest, Abdomen and Arm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Venous Stents by Application - Leg, Chest, Abdomen and Arm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Venous Stents by Application - Percentage Breakdown of Value Sales for Leg, Chest, Abdomen and Arm for the Years 2014, 2024 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Venous Stents by Disease Indication - Percentage Breakdown of Value Sales for Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Venous Stents by Technology - Percentage Breakdown of Value Sales for Iliac Vein Stent Technology and Wallstent Technology for the Years 2014, 2024 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Venous Stents by Application - Leg, Chest, Abdomen and Arm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Venous Stents by Application - Leg, Chest, Abdomen and Arm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Venous Stents by Application - Percentage Breakdown of Value Sales for Leg, Chest, Abdomen and Arm for the Years 2014, 2024 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Venous Stents by Disease Indication - Percentage Breakdown of Value Sales for Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Venous Stents by Technology - Percentage Breakdown of Value Sales for Iliac Vein Stent Technology and Wallstent Technology for the Years 2014, 2024 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Venous Stents by Application - Leg, Chest, Abdomen and Arm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Venous Stents by Application - Leg, Chest, Abdomen and Arm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Venous Stents by Application - Percentage Breakdown of Value Sales for Leg, Chest, Abdomen and Arm for the Years 2014, 2024 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Venous Stents by Disease Indication - Percentage Breakdown of Value Sales for Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Venous Stents by Technology - Percentage Breakdown of Value Sales for Iliac Vein Stent Technology and Wallstent Technology for the Years 2014, 2024 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Venous Stents by Application - Leg, Chest, Abdomen and Arm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Venous Stents by Application - Leg, Chest, Abdomen and Arm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Venous Stents by Application - Percentage Breakdown of Value Sales for Leg, Chest, Abdomen and Arm for the Years 2014, 2024 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Venous Stents by Disease Indication - Percentage Breakdown of Value Sales for Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications for the Years 2014, 2024 & 2030
  • AFRICA
    • Venous Stents Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Venous Stents by Technology - Iliac Vein Stent Technology and Wallstent Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Venous Stents by Technology - Percentage Breakdown of Value Sales for Iliac Vein Stent Technology and Wallstent Technology for the Years 2014, 2024 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Venous Stents by Application - Leg, Chest, Abdomen and Arm - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Venous Stents by Application - Leg, Chest, Abdomen and Arm Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Venous Stents by Application - Percentage Breakdown of Value Sales for Leg, Chest, Abdomen and Arm for the Years 2014, 2024 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Venous Stents by Disease Indication - Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Venous Stents by Disease Indication - Percentage Breakdown of Value Sales for Chronic Deep Vein Thrombosis, Post Thrombotic Syndrome, May-Thurner Syndrome, Hemodialysis/Arteriovenous Fistulae and Other Disease Indications for the Years 2014, 2024 & 2030

IV. COMPETITION